First human tests begin for new Immune-Targeting diabetes drug

NCT ID NCT06324604

Recruiting now Knowledge-focused Sponsor: Mozart Therapeutics Australia Pty Ltd Source: ClinicalTrials.gov ↗

Summary

This is the first study in humans for a new drug called MTX-101. Researchers want to understand its safety, how long it stays in the body, and how it affects immune cells. The study will involve healthy adults and people with type 1 diabetes to gather initial data.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Austin Health
RECRUITING

Heidelberg, Victoria, 3084, Australia

Contact
St Vincent's Hospital Melbourne (SVHM)
RECRUITING

Melbourne, Victoria, Austria

Contact
The Royal Melbourne Hospital
RECRUITING

Melbourne, Victoria, 3050, Australia

Contact
Wesley Research Institute
ACTIVE_NOT_RECRUITING

Auchenflower, Queensland, 4066, Australia

Conditions

Explore the condition pages connected to this study.

HEALTHY VOLUNTEERS TYPE 1 DIABETES